Inhibiting Rab11b reduced the invasiveness
of a breast cancer cell line, called MDA - MB - 231, that expresses high amounts of Arf6 signaling proteins, the researchers discovered.
This statement is based on two reports showing that soy caused a small stimulation of normal breast cancer tissue and a report that genistein, one of the phytoestrogens found in soy, stimulated the rate of growth
of breast cancer cells in mice lacking both their ovaries and a functioning immune system.
Gene therapy delivered directly to a particularly stubborn
type of breast cancer cell causes the cells to self - destruct, lowers chance of recurrence and helps increase the effectiveness of some types of chemotherapy, researchers...
To directly examine whether ABL kinases play a role in regulating the colonization and
survival of breast cancer cells in the bone microenvironment, we injected control or ABL1 / ABL2 knockdown breast cancer cells directly into the tibia of immunodeficient mice.
Our data raise the possibility that inhibition of ABL kinases can increase
apoptosis of breast cancer cells and block osteoclast activation, which is required for osteolytic metastasis.
In a study published in Toxicology and Applied Pharmacology, researchers found that broccoli and watercress suppressed the production of cancer - promoting enzymes known as matrix metalloproteinases, thereby limiting the
invasiveness of breast cancer cells.
Another study out of Japan found that infrared - induced, whole - body hyperthermia helped strongly inhibit the growth and
spread of breast cancer cells in mice, without causing any harmful side effects.
New evidence however is showing that not only is there not a risk, but that soy is actually beneficial in terms of mortality and reducing the
recurrence of breast cancer cells.
In contrast, S1P treatment
of breast cancer cells does not activate matriptase, and instead these cells constitutively activate the protease.
To gain insight into the signaling pathway (s) required for ABL1 / ABL2 - dependent bone metastasis, we evaluated the consequences of single or double inactivation of ABL1 and ABL2 on the transcriptome
of breast cancer cells using next - generation sequencing (RNAseq) analysis (Fig. 6 and fig.
Researchers at Roswell Park Cancer Institute (RPCI) have identified a
mechanism of breast cancer cells that leads to chemotherapy resistance in inflammatory breast cancer.
The investigators tested a
variety of breast cancer cell types, including tamoxifen - sensitive cells that are resistant to the drug lapatinib, another targeted therapy that is used to treat patients with advanced breast cancer whose tumors contain the mutant HER2 gene.
Scientists at the Computational Biology Center in IBM Research provided analytics tools and performed analysis of the data to help tease out the biological mechanisms at play in studying the
micro-environment of breast cancer cells.
The identification of patients with high - risk breast cancer is key to knowing whether a patient will require only the removal of the tumor by surgery or whether if she will need additional chemotherapy to make sure the
removal of breast cancer cells.
The Arf6 pathway may also boost the drug
resistance of breast cancer cells, and Hashimoto et al. found that inhibiting Rab11b, or a component of the Arf6 pathway called EPB41L5, increased the sensitivity of MDA - MB - 231 cells to two different cytotoxic compounds.
Interestingly, Yu and colleagues recently showed that knockdown of KLF4 decreased the proportion of cancer stem cells, whereas overexpression of this gene led to an increase in the cancer stem cell population, suggesting that KLF4 plays a strong oncogenic role in mammary tumorigenesis likely by maintaining stem cell - like
futures of breast cancer cells (29).
In support of this notion, KLF4 has been found to be frequently overexpressed in 70 % of breast cancers, and its localization in the
nucleus of breast cancer cells has been identified as a marker of aggressive phenotype in early - stage infiltrating ductal carcinoma (30).
Dr. Vines is frequently analyzing models used to understand how CCR7 affects the
movement of breast cancer cells and T cell acute lymphocytic leukemia cells.
Matriptase and its cognate inhibitor, HGF activator inhibitor 1 (HAI - 1) colocalize on the cell
periphery of breast cancer cells and form stable complexes in the extracellular milieu, suggesting that the inhibitor serves to prevent undesired proteolysis in these cells.
Quantitative proteomics
study of breast cancer cell lines isolated from a single patient: discovery of TIMM17A as a marker for breast cancer.
Subpopulations of breast cancer cells sometimes cooperate to aid tumor growth, according to Penn State College of Medicine researchers, who believe that understanding the relationship between cancer subpopulations could lead to new targets for cancer treatment.
«We may have found a root source, maybe the root source, of what ultimately determines the
destiny of breast cancer cells — their future benign or aggressive clinical behavior,» says Whitehead Founding Member Robert Weinberg, who is also a professor of biology at MIT and Director of the MIT / Ludwig Center for Molecular Oncology.
Treatment of tumor - bearing mice with GNF5 starting on day 8 after intracardiac
injection of breast cancer cells (Fig. 3A) resulted in a significant increase in survival (Fig. 3B) and a decrease in bone metastasis burden as measured by bioluminescence imaging (Fig. 3, C and D).